US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...
Earnings season is now well under way, with a number of major companies due to release results in the coming week. Investors ...
Organization highlights transformative approaches to clinical research, operational efficiency and patient-centric care at SCOPE US 2025 PH ...
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback